← Leaderboards
Debasish Sinha
Johns Hopkins University
$7,181,987
Attributed
$8,398,133
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2008–24$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,398,133 · 6
By mechanism
R01$7,785,683 · 4
R21$448,950 · 1
R03$163,500 · 1
Top collaborators
- James T Handa5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Peter A Campochiaro$21,020,539
- Mei Wan$12,070,256
- Xu Cao$21,394,088
- Janet Crane$3,964,821
- Konstantinos Konstantopoulos$20,830,912
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantCrystallinsAffectRetinaProteinsPhenotypeBaseMouse ModelMolecularMutationRattusCell PhysiologyEndothelial CellsCellsMigrationFetalAstrocytesVimentinCell MotilityGenesPlayInsightBinding (Molecular Function)Exhibits
Grant awards (21)
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy$584,501
R01 · FY2024 · EY · contact PI
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy$17,789
R01 · FY2024 · EY · contact PI
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy$607,796
R01 · FY2023 · EY · contact PI
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy$594,408
R01 · FY2022 · EY · contact PI
Function of a lens protein betaA3/A1-crystallin in astrocytes$397,500
R01 · FY2022 · EY · contact PI
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy$627,798
R01 · FY2021 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$470,116
R01 · FY2015 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$470,116
R01 · FY2014 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$455,724
R01 · FY2013 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$468,371
R01 · FY2012 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$389,664
R01 · FY2011 · EY · contact PI
A CRYSTALLIN MUTATION WITH ABNORMAL ASTROCYTES AND RETINAL VESSELS$410,000
R01 · FY2010 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$405,900
R01 · FY2010 · EY · contact PI
Genetic analysis of a spontaneous mutation in a rat with a novel hind limb defect$202,950
R21 · FY2010 · HD · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$656,000
R01 · FY2009 · EY · contact PI
A CRYSTALLIN MUTATION WITH ABNORMAL ASTROCYTES AND RETINAL VESSELS$410,000
R01 · FY2009 · EY · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$410,000
R01 · FY2009 · EY · contact PI
Genetic analysis of a spontaneous mutation in a rat with a novel hind limb defect$246,000
R21 · FY2009 · HD · contact PI
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature$410,000
R01 · FY2008 · EY · contact PI
MODULATION OF CIITA BY CANNABINOIDS IN HUMAN MICROGLIA$81,750
R03 · FY2004 · DA
MODULATION OF CIITA BY CANNABINOIDS IN HUMAN MICROGLIA$81,750
R03 · FY2003 · DA